Dementia Drugs Market By Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Dementia Drugs Market

Dementia is not a specific disease but is rather a general term for the impaired ability to remember, think, or make decisions that interferes with doing everyday activities. Alzheimer’s disease is the most common type of dementia. Though dementia mostly affects older adults, it is not a part of normal aging. Because dementia is a general term, its symptoms can vary widely from person to person. People with dementia have problems with memory, communication, reasoning, and problem solving. A healthcare provider can perform tests on attention, memory, problem solving, and other cognitive abilities to see if there is cause for concern. A physical exam, blood tests, and brain scans like a CT or MRI can help determine an underlying cause. Treatment of dementia depends on the underlying cause. Neurodegenerative dementias, like Alzheimer’s disease, have no cure, though there are medications that can help protect the brain or manage symptoms, such as anxiety or behavior changes. Research to develop more treatment options is ongoing. Leading a healthy lifestyle, including regular exercise, healthy eating, and maintaining social contacts, decreases chances of developing chronic diseases and may reduce the number of people with dementia.

The key factors that drive the growth of the market are increase in the prevalence of Alzheimer’s disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. Moreover, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, and increase in public awareness about the disease prevention in developing regions are further expected to boost the dementia drugs industry growth during forecast period. However, strict government regulation related to product approval and high cost linked to R& D activity is likely to hamper the growth of the dementia drugs market during the forecast period. Conversely, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are expected to provide numerous opportunities for market growth during the forecast period. By indication, the Alzheimer's Disease segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to increase in life expectancy, rise in ageing population, and changes in lifestyle. In addition, the growth is associated with rapid improvement in medical infrastructure, increase in scientific studies associated with the treatment and monitoring of Alzheimer's disease, as well as significant government and private sector funding in the Alzheimer's research, which further propel the market growth.

Depending on drug class, the cholinesterase inhibitors segment dominated the dementia drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in prevalence of dementia and growth in drug discovery. .In addition, certain factors such as emerging technologies, developing markets, and government initiatives toward R&D of Alzheimer’s therapeutics further boost the dementia drugs market trends.

By distribution channel, the hospital pharmacies segment dominated the dementia drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in geriatric population and Alzheimer’s patients.

Region-wise,dementia drugs market analysis across North America, Europe, asia-Pacific and LAMEA. North America has the highest market share, with $3657.17 million in 2021, and is estimated to reach $7270.88 million by 2031, registering a CAGR of 7.1% during the forecast period, owing to investments made by key players for various R&D activities as well as launch of new products in the U.S. In addition, increase in awareness among consumers for the adoption of dementia drugs is further anticipated to stimulate the growth of the dementia drugs industry in North America. On the other side, Asia-Pacific is projected to register the highest CAGR of 10.6% during the dementia drugs market forecast period. The evolving healthcare regulatory landscape, increase in the number of patients with chronic diseases, and the government's emphasis on enhancing R&D capabilities for innovative drug development are the key driving factors that boost the growth of the market.

 

Key findings of the study

On the basis of indication, the Alzheimer’s disease segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

On the basis of drug class, the cholinesterase inhibitors segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

Depending on distribution channel, the hospitals pharmacies segment is projected to grow at a CAGR of 7.0% during the forecast period.

Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 10.6% during the forecast period.

Overview

The global dementia drugs market accounted for $8662.17 million in 2021, and is expected to reach $19704.27 million by 2031, registering a CAGR of 8.5% from 2022 to 2031.

Dementia is a syndrome in which there is deterioration in thinking, behavior, memory, and ability to perform daily activities. The most common form of dementia is Alzheimer disease. Dementia results from many injuries and disease that primarily or secondarily impact the brain. There is often lack of awareness about dementia, which results in obstacles to examination and care. Cholinesterase Inhibitors are most commonly prescribed medicines, which help prevent break down of acetylcholine in the brain as acetylcholine is essential in learning, memory, and mood of individual.

It is estimated that the dementia drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Alzheimer’s disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine, further facilitate the growth of the market. However, strict government regulation related to product approval and high cost linked to R&D activity are expected to impede the market growth. In contrast, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are factors that present new pathway in the industry, which are anticipated to provide significant growth opportunities for the dementia drugs market.

The dementia drugs market is segmented on the basis of indication, drug class, distribution channel, and region. On the basis of indication, the market is bifurcated into Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and other indications. Depending on drug class, the market is classified into cholinesterase inhibitors and NMDA antagonist and its combination drugs. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global dementia dugs market. The key companies profiled in the report include AbbVie Inc., APPOTEX Inc., Aurobindo Pharma Limited, Biogen Idec Inc., EISAI GLOBAL, Eli Lilly and company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG and Teva Pharmaceuticals

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dementia drugs market analysis from 2021 to 2031 to identify the prevailing dementia drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the dementia drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global dementia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Novartis A

Scope of Dementia Drugs Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Lewy Body Dementia

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Parkinsons Disease Dementia

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

4.4 Alzheimers Disease

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market share analysis by country

4.5 Vascular Dementia

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market share analysis by country

4.6 Other Indications

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Cholinesterase Inhibitors

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 NMDA Antagonists and its Combination Drugs

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Retail Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Hospital Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Online Pharmacies

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Indication

7.2.3 North America Market size and forecast, by Drug Class

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Indication

7.2.5.1.3 Market size and forecast, by Drug Class

7.2.5.1.4 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Indication

7.2.5.2.3 Market size and forecast, by Drug Class

7.2.5.2.4 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Indication

7.2.5.3.3 Market size and forecast, by Drug Class

7.2.5.3.4 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Indication

7.3.3 Europe Market size and forecast, by Drug Class

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Indication

7.3.5.1.3 Market size and forecast, by Drug Class

7.3.5.1.4 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Indication

7.3.5.2.3 Market size and forecast, by Drug Class

7.3.5.2.4 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Indication

7.3.5.3.3 Market size and forecast, by Drug Class

7.3.5.3.4 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Indication

7.3.5.4.3 Market size and forecast, by Drug Class

7.3.5.4.4 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Indication

7.3.5.5.3 Market size and forecast, by Drug Class

7.3.5.5.4 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Indication

7.3.5.6.3 Market size and forecast, by Drug Class

7.3.5.6.4 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Indication

7.4.3 Asia-Pacific Market size and forecast, by Drug Class

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 China

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Indication

7.4.5.1.3 Market size and forecast, by Drug Class

7.4.5.1.4 Market size and forecast, by Distribution Channel

7.4.5.2 Japan

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Indication

7.4.5.2.3 Market size and forecast, by Drug Class

7.4.5.2.4 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Indication

7.4.5.3.3 Market size and forecast, by Drug Class

7.4.5.3.4 Market size and forecast, by Distribution Channel

7.4.5.4 South Korea

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Indication

7.4.5.4.3 Market size and forecast, by Drug Class

7.4.5.4.4 Market size and forecast, by Distribution Channel

7.4.5.5 Australia

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Indication

7.4.5.5.3 Market size and forecast, by Drug Class

7.4.5.5.4 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Indication

7.4.5.6.3 Market size and forecast, by Drug Class

7.4.5.6.4 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Indication

7.5.3 LAMEA Market size and forecast, by Drug Class

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Indication

7.5.5.1.3 Market size and forecast, by Drug Class

7.5.5.1.4 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Indication

7.5.5.2.3 Market size and forecast, by Drug Class

7.5.5.2.4 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Indication

7.5.5.3.3 Market size and forecast, by Drug Class

7.5.5.3.4 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Indication

7.5.5.4.3 Market size and forecast, by Drug Class

7.5.5.4.4 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 apotex inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Aurobindo Pharma Ltd

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Biogen Idec

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Eisai

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Eli Lilly and Company

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Johnson & Johnson

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Abbvie Inc

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 , F. Hoffmann-La Roche AG

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Teva Pharmaceutical Industries

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Novartis AG

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 2. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 8. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 10. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 11. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 12. GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 13. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 14. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 15. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 16. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 17. GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 18. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 20. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 21. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 22. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 23. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 24. DEMENTIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 25. NORTH AMERICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 26. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 27. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 28. NORTH AMERICA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 29. U.S. DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 30. U.S. DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 31. U.S. DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 32. CANADA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 33. CANADA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 34. CANADA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 35. MEXICO DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 36. MEXICO DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 37. MEXICO DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 38. EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 39. EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 40. EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 41. EUROPE DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 42. GERMANY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 43. GERMANY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 44. GERMANY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 45. FRANCE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 46. FRANCE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 47. FRANCE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 48. UK DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 49. UK DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 50. UK DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 51. ITALY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 52. ITALY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 53. ITALY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 54. SPAIN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 55. SPAIN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 56. SPAIN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 57. REST OF EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 58. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 59. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 60. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 61. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 62. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 63. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 64. CHINA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 65. CHINA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 66. CHINA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 67. JAPAN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 68. JAPAN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 69. JAPAN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 70. INDIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 71. INDIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 72. INDIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 73. SOUTH KOREA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 74. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 75. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 76. AUSTRALIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 77. AUSTRALIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 78. AUSTRALIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 79. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 80. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 81. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 82. LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 83. LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 84. LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 85. LAMEA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 86. BRAZIL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 87. BRAZIL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 88. BRAZIL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 89. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 90. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 91. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 92. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 93. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 94. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 95. REST OF LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 96. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)

TABLE 97. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 98.APOTEX INC.: COMPANY SNAPSHOT

TABLE 99.APOTEX INC.: OPERATING SEGMENTS

TABLE 100.APOTEX INC.: PRODUCT PORTFOLIO

TABLE 101.APOTEX INC.: NET SALES

TABLE 102.APOTEX INC.: KEY STRATERGIES

TABLE 103.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT

TABLE 104.AUROBINDO PHARMA LTD: OPERATING SEGMENTS

TABLE 105.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO

TABLE 106.AUROBINDO PHARMA LTD: NET SALES

TABLE 107.AUROBINDO PHARMA LTD: KEY STRATERGIES

TABLE 108.BIOGEN IDEC: COMPANY SNAPSHOT

TABLE 109.BIOGEN IDEC: OPERATING SEGMENTS

TABLE 110.BIOGEN IDEC: PRODUCT PORTFOLIO

TABLE 111.BIOGEN IDEC: NET SALES

TABLE 112.BIOGEN IDEC: KEY STRATERGIES

TABLE 113.EISAI: COMPANY SNAPSHOT

TABLE 114.EISAI: OPERATING SEGMENTS

TABLE 115.EISAI: PRODUCT PORTFOLIO

TABLE 116.EISAI: NET SALES

TABLE 117.EISAI: KEY STRATERGIES

TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS

TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 121.ELI LILLY AND COMPANY: NET SALES

TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES

TABLE 123.JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 124.JOHNSON & JOHNSON: OPERATING SEGMENTS

TABLE 125.JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 126.JOHNSON & JOHNSON: NET SALES

TABLE 127.JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 128.ABBVIE INC: COMPANY SNAPSHOT

TABLE 129.ABBVIE INC: OPERATING SEGMENTS

TABLE 130.ABBVIE INC: PRODUCT PORTFOLIO

TABLE 131.ABBVIE INC: NET SALES

TABLE 132.ABBVIE INC: KEY STRATERGIES

TABLE 133., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

TABLE 134., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS

TABLE 135., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

TABLE 136., F. HOFFMANN-LA ROCHE AG: NET SALES

TABLE 137., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES

TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT

TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS

TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO

TABLE 141.TEVA PHARMACEUTICAL INDUSTRIES: NET SALES

TABLE 142.TEVA PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES

TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 144.NOVARTIS AG: OPERATING SEGMENTS

TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 146.NOVARTIS AG: NET SALES

TABLE 147.NOVARTIS AG: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.DEMENTIA DRUGS MARKET SEGMENTATION

FIGURE 2.DEMENTIA DRUGS MARKET,2021-2031

FIGURE 3.DEMENTIA DRUGS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.DEMENTIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.DEMENTIA DRUGS MARKET,BY INDICATION,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LEWY BODY DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PARKINSONS DISEASE DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF VASCULAR DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 18.DEMENTIA DRUGS MARKET,BY DRUG CLASS,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHOLINESTERASE INHIBITORS DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NMDA ANTAGONISTS AND ITS COMBINATION DRUGS DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 21.DEMENTIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)

FIGURE 25.DEMENTIA DRUGS MARKET BY REGION,2021

FIGURE 26.U.S. DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 27.CANADA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 28.MEXICO DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 29.GERMANY DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 30.FRANCE DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 31.UK DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 32.ITALY DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 33.SPAIN DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 34.REST OF EUROPE DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 35.CHINA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 36.JAPAN DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 37.INDIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 38.SOUTH KOREA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 39.AUSTRALIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 40.REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 41.BRAZIL DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 42.SAUDI ARABIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 43.SOUTH AFRICA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 44.REST OF LAMEA DEMENTIA DRUGS MARKET,2021-2031($MILLION)

FIGURE 45. TOP WINNING STRATEGIES, BY YEAR

FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 49.COMPETITIVE DASHBOARD

FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 51.APOTEX INC..: NET SALES ($MILLION)

FIGURE 52.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)

FIGURE 53.BIOGEN IDEC.: NET SALES ($MILLION)

FIGURE 54.EISAI.: NET SALES ($MILLION)

FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)

FIGURE 56.JOHNSON & JOHNSON.: NET SALES ($MILLION)

FIGURE 57.ABBVIE INC.: NET SALES ($MILLION)

FIGURE 58., F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)

FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES.: NET SALES ($MILLION)

FIGURE 60.NOVARTIS AG.: NET SALES ($MILLION